Haematologica (Aug 2022)

Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia

  • Elise Sourdeau,
  • Ludovic Suner,
  • Mara Memoli,
  • Alexis Genthon,
  • Frédéric Feger,
  • Lou Soret,
  • Nasséra Abermil,
  • Laurence Heuberger,
  • Chrystele Bilhou-Nabera,
  • Hélène Guermouche,
  • Fabrizia Favale,
  • Simona Lapusan,
  • Michael Chaquin,
  • Claire Hirschauer,
  • Mohamad Mohty,
  • Ollivier Legrand,
  • François Delhommeau,
  • Pierre Hirsch

DOI
https://doi.org/10.3324/haematol.2022.280676
Journal volume & issue
Vol. 108, no. 1

Abstract

Read online

Chemotherapy resistance is the main cause of treatment failure in acute myeloid leukemia (AML) and has been related to ATP-binding cassette (ABC) transporter activity. However, the links between ABC activity, immunophenotype, and molecular AML parameters have been poorly evaluated. Moreover, the prognostic value of ABC activity, when compared to new molecular markers, is unknown. Here we investigated the links between ABC activity, as evaluated by JC-1 +/- cyclosporine A assay, and immunophenotypic, cytogenetic, molecular, and targeted next-generation sequencing features in 361 AML patients. High ABC activity was found in 164 patients and was significantly associated with less proliferating disease, an immature immunophenotype (expression of CD34, HLA-DR, CD117, CD13), and gene mutations defining AML as belonging to secondary-type ontogenic groups. Low ABC activity was associated with more mature myeloid differentiation (CD34-, cyMPO+, CD15+, CD33+) or monocytic commitment (CD64+, CD4+weak, CD14+), with NPM1 mutations, KMT2A rearrangements, and core-binding factor gene fusions, hallmarks of the de novo-type AML ontogeny. ABC activity was one of the major factors we identified using a random forest model for early prediction of AML ontogeny. In the 230 patients evaluated at diagnosis and intensively treated, high ABC activity was a predictive factor for primary resistance, and in multivariate analysis including full molecular data, an independent factor for event-free survival (P=0.0370). JC-1 +/- cyclosporine A assay could be used at diagnosis to predict AML ontogeny and to complete prognosis evaluation in addition to new molecular markers.